A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram

Journal of Clinical Psychiatry

Volumn 74, Issue 8, 2013, Pages 802-809

  Trivedi, Madhukar H ^a   Cutler, Andrew J ^b   Richards, Cynthia ^c   Lasser, Robert ^e   Geibel, Brooke B ^d   Gao, Joseph ^d   Sambunaris, Angelo ^f,g   Patkar, Ashwin A ^h  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Florida Clinical Research Center LLC   (United States)

^c Global Clinical Development and Innovation   (United States)

^d Clinical Development Operations and Biometrics   (United States)

^e SHIRE   (United States)

^f SYNEOS HEALTH   (United States)

^g Atlanta Medical Research Institute   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; LISDEXAMFETAMINE; PLACEBO;

ABNORMAL DREAMING; ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAMILTON SCALE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84883150328     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08360     Document Type: Article

References (27)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al; STARD Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry. 2006;163(11):1905-1917.
3. Trivedi MH, Fava M, Wisniewski SR, et al; STARD Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
4. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59(suppl 5):60-63, discussion 64.
5. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70(suppl 5):12-17.
6. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93.
7. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153-159.
8. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70(suppl 5): 18-22.
9. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebocontrolled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653-656.
10. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder, third edition. http://guidelines.gov/content.aspx?id=24158. Accessed May 19, 2011.
11. Vyvanse (lisdexamfetamine dimesylate) [package insert]. Wayne, PA: Shire US Inc; 2012.
12. First MB, Williams JBW, Spitzer RL, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2007.
13. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
16. Guy W. Clinical global improvement scale. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338; Rockville, MD: National Institute of Mental Health; 1976:218-222.
17. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and selfreport (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
18. Medical Dictionary for Regulatory Activities Terminology (MedDRA) version 11.1. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). http://meddramsso.com/ index.asp. Accessed July 11, 2013.
19. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale. http://www.maps.org/mdma/mt1-docs/c-ssrs1-14-09-baseline.pdf. Accessed May 14, 2013.
20. Geibel B, Cutler A, Richards C, et al. Demographics and open-label escitalopram therapy in adults with major depressive disorder: prior to adjunctive lisdexamfetamine dimesylate or placebo. In: 164th Annual Meeting of the American Psychiatric Association; May 14-18, 2011; Honolulu, HI.
21. Madhoo M, Keefe RSE, Roth RM, et al. Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder [abstract]. Int J Neuropsychopharmacol. 2012;15(suppl 1):189.
22. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
23. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
24. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
25. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry. 2008;69(1):87-94.
26. DeBattista C, Doghramji K, Menza MA, et al Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary doubleblind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-1064.
27. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a doubleblind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(6):614-619.